Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shGal-1
- Development stage
- Preclinical
- Lead developer
- University of Illinois College of Medicine
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
shGal-1 is a short hairpin RNA (shRNA) therapeutic candidate designed to silence the expression of Galectin-1 (Gal-1), a protein that plays a pivotal role in the progression of glioblastoma multiforme (GBM) and the maintenance of glioma stem cells. By targeting Gal-1 mRNA for degradation, shGal-1 reduces the levels of Gal-1 protein, which in turn downregulates the expression of CD147 (Basigin) and matrix metalloproteinase-9 (MMP9). This inhibition disrupts the Gal-1-CD147-MMP9 signaling axis, which is associated with tumor cell invasion, integrin regulation, and poor overall survival in GBM patients. Currently utilized in preclinical research, shGal-1 serves as a tool to validate Gal-1 as a therapeutic target for high-grade gliomas.
- Other names
- shRNA targeting Galectin-1Galectin-1 shRNAGalectin1 shRNAGalectin 1 shRNA
02
Targets
LGALS1 (Galectin-1)
Beyond the preview
Go deeper on shGal-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shGal-1.